The Pharmacy Times® Insights video library presents one-on-one interviews with pharmacy experts, who examine the latest patient counseling tools and innovative solutions for the everyday practice and business.
What can we help you find?
Experts in the field of chronic lymphocytic management [CLL] discuss important disease-related factors to take into consideration when determining a patient’s therapy regimen.
Katie Culos, PharmD, BCOP and Daniel Wojenski, PharmD, BCPS, BCOP discuss the NCCN (National Comprehensive Cancer Center)-recommended front-line treatment options for patients with newly diagnosed CLL ([chronic lymphocytic leukemia)].
Jacob Kettle, PharmD, BCOP, and Allison Butts, PharmD, BCOP, share some future therapies for the management of breast cancer.
Jacob Kettle, PharmD, BCOP, and Allison Butts, PharmD, BCOP, consider the influence of COVID-19 on the therapeutic choice for patients.
A discussion on the impact and the use of telehealth in the management of patients during the COVID-19 pandemic.
The panel of pharmacists provides input on pharmacists’ role in managing novel therapeutic agents and transitioning patients from IV to SQ dosing.
Jacob Kettle, PharmD, BCOP, reviews some potential barriers to adding novel agents to the armamentarium for the management of breast cancer.
Jacob Kettle, PharmD, BCOP, and Allison Butts, PharmD, BCOP, discuss the loading dose for IV vs SQ and the reduced chair-time with SQ. They also talk about the improved quality of life for patients without a porta-a-cath.
The panel of pharmacists share data for the recently approved subcutaneous pertuzumab + trastuzumab combination therapy from the FeDeriCa study.
Jacob Kettle, PharmD, BCOP, and Allison Butts, PharmD, BCOP, discuss the role of biosimilars in the management of breast cancer.
A review of the potential agents or regimens that Allison Butts, PharmD, BCOP, is looking forward to seeing transition from metastatic management to the early stage setting.
Experts in the field of breast cancer management review the data from the ExteNET and TRAIN-2 Trials.